Email Page Print Page

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

2013 Archives

Dec 3, 2013
Position provides the ability to execute commercialization options for BUNAVAIL and other BDSI products
Dec 2, 2013
Phase 3 to begin first quarter 2014; Fast track designation confirmed for NDA program
Oct 21, 2013
Experienced industry veteran augments BDSI's executive management team as company moves toward finalization of its commercial options for BUNAVAIL and explores further business development opportunities
Oct 9, 2013
FDA decision on approval of BUNAVAIL expected by early June 2014
Sep 4, 2013
on BEMA Buprenorphine Phase III Development Program
Aug 9, 2013
BUNAVAIL NDA submitted to FDA; first buccal film to compete in growing opioid dependence marketplace
Aug 1, 2013
First buprenorphine naloxone buccal film for the maintenance treatment of opioid dependence
Jul 8, 2013
Financing strengthens cash position as BDSI approaches BUNAVAIL NDA submission and BEMA Buprenorphine Phase 3 study completion
Jun 10, 2013
BUNAVAIL NDA submission continues on target for mid-summer 2013
Mar 26, 2013
Completed Phase 2 study demonstrated efficacy in a pain condition with significant unmet need
Mar 18, 2013
NDA filing for BEMA Buprenorphine/Naloxone (BUNAVAIL) on track for mid-2013